Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients
Launched by CAIRO UNIVERSITY · Nov 24, 2021
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
After randomization, Treatment and control groups will receive Parkland formula (4 ml/kg per percent total burn surface area; (TBSA), counting moderate (partial thickness) and severe (full thickness) burn area only) using Ringer's lactate solution (half of the fluid will be given over the first eight hours and the remaining half will be given over the next 16 hours), plus normal 24-hour maintenance fluid requirements using glucose solution.
When initiating Parkland, treatment group (Group A) will receive intravenous immunoglobulin IVIG (LIV-GAMMA "S/D treated Human Immunoglobulin" 2.5 gram...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All burn patients 1 to 5 years old with 10% or greater burn area of TBSA .
- Exclusion Criteria:
- • Patients with septic shock (evidence of infection and inotropes) .
- • Burns more than 48 hours duration.
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Trial Officials
Hanan Mostafa
Principal Investigator
lecturer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials